patient
underw
allogen
syngen
autolog
hct
fred
hutchinson
cancer
research
center
seattl
cancer
center
allianc
seattl
washington
novemb
june
analyz
patient
respiratori
symptom
respiratori
secret
analyz
respiratori
virus
accord
institut
protocol
receiv
standard
care
rsv
diseas
patient
rsv
uri
receiv
high
dose
intermitt
gday
mgml
hour
everi
hour
low
dose
continu
gday
mgml
hoursday
ribavirin
discret
attend
physician
without
immunoglobulin
monoclon
antibodi
direct
fusion
protein
rsv
palivizumab
use
steroid
intraven
immunoglobulin
ivig
palivizumab
time
rsv
infect
also
analyz
steroid
given
patient
acut
graft
vs
host
diseas
gvhd
ivig
given
mainli
gvhd
prophylaxi
low
immunoglobulin
level
maximum
mgkgweek
januari
routin
ivig
administr
discontinu
patient
sign
consent
allow
retrospect
research
includ
studi
studi
approv
fred
hutchinson
cancer
research
center
institut
review
board
patient
develop
respiratori
tract
ill
due
confirm
rsv
infect
consid
rsv
infect
patient
present
rsv
uri
within
day
post
hct
includ
analysi
rsv
uri
defin
respiratori
infect
confin
nose
throat
sinus
confirm
detect
rsv
without
evid
lower
respiratori
tract
involv
rsv
lrd
defin
detect
rsv
lower
respiratori
tract
bronchoalveolar
lavag
bal
biopsi
patient
lower
respiratori
tract
symptom
cough
oxygen
requir
wheez
radiograph
new
infiltr
patient
uri
defin
nonprogressor
patient
uri
initi
subsequ
progress
lrd
defin
progressor
patient
present
rsv
lrd
concurr
uri
defin
develop
lrd
within
day
rsv
uri
exclud
respiratori
specimen
nasopharyng
washswab
bal
sampl
studi
viral
antigen
detect
direct
fluoresc
antibodi
dfa
stain
rsv
influenza
b
parainfluenza
adenoviru
human
metapnuemoviru
sinc
april
convent
shell
vial
centrifug
viral
cultur
perform
standard
practic
patient
throughout
studi
period
upper
respiratori
tract
sampl
test
polymeras
chain
reaction
pcr
instead
convent
method
wherea
bal
sampl
test
convent
method
pcr
cultur
rsv
isol
store
total
nucleic
acid
extract
sampl
test
rsv
rna
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
assay
describ
elsewher
rsv
type
specif
assay
contain
one
primer
set
amplifi
bp
region
rsv
polymeras
gene
type
b
probe
specif
rsv
type
viclabel
probe
specif
rsv
type
b
probe
label
end
mgbnfq
test
avail
sera
prospect
collect
serum
repositori
mostli
collect
pretranspl
sera
donor
hct
recipi
weekli
posttranspl
sera
close
uri
event
within
week
week
analyz
sampl
sera
store
measur
serum
neutralizingantibodi
titer
rsv
perform
use
establish
microneutr
method
rsv
mna
rsv
b
mnb
strain
laboratori
dr
walsh
univers
rochest
brief
serum
dilut
incub
plaqueform
unit
pfu
rsv
strain
group
viru
rsv
strain
group
b
viru
minut
room
temperatur
follow
addit
cell
cultur
plate
day
quantiti
rsv
antigen
determin
eia
use
monoclon
antibodi
mab
rsv
f
protein
neutral
titer
defin
serum
dilut
result
reduct
color
develop
probabl
progress
upper
lower
rsv
infect
estim
use
cumul
incid
death
treat
compet
risk
progress
differ
proport
patient
progress
lrd
evalu
statist
signific
logist
regress
model
follow
variabl
consid
potenti
predictor
progress
patient
age
sex
smoke
statu
donor
type
cell
sourc
donor
recipi
cmv
serostatu
year
transplant
perform
total
bodi
irradi
tbi
condit
presenc
acut
gvhd
lymphocyt
count
time
rsv
uri
onset
pretranspl
lung
function
rsv
subtyp
time
transplant
rsv
infect
ribavirin
treatment
steroid
treatment
vari
dose
rsv
antibodi
level
weekli
ivig
infus
grade
acut
gvhd
consid
present
diagnos
day
diagnosi
upper
rsv
infect
patient
receiv
autolog
syngen
transplant
categor
separ
analysi
acut
gvhd
risk
factor
progress
antibodi
level
classifi
accord
rsv
subtyp
covari
least
complet
data
candid
primari
analysi
via
multipl
logist
regress
model
variabl
retain
multivari
model
univari
associ
progress
result
p
valu
ribavirin
treatment
retain
model
predictor
interest
covari
miss
data
includ
first
round
multivari
model
subsequ
examin
subset
patient
avail
data
statist
signific
differ
absolut
lymphocyt
count
alc
time
uri
onset
lrd
onset
progressor
time
uri
onset
day
later
nonprogressor
evalu
wilcoxon
sign
rank
test
differ
alc
valu
slope
chang
alcday
uri
lrd
compar
progress
statu
via
ttest
report
p
valu
base
wald
statist
adjust
made
multipl
comparison
statist
analys
perform
use
sa
version
sa
institut
inc
cari
nc
univari
model
tabl
smoke
statu
transplant
year
high
tbi
dose
condit
regimen
lymphocyt
count
uri
onset
time
uri
onset
suffici
predict
progress
lrd
qualifi
multivari
model
multivari
model
tabl
left
side
includ
patient
progressor
posit
smoke
statu
tbi
cgi
lymphocyt
count
less
time
rsv
uri
onset
signific
risk
factor
progress
lrd
note
treatment
highdos
ribavirin
reach
statist
signific
includ
model
determin
risk
factor
differ
consid
lrd
event
confirm
radiograph
infiltr
addit
model
fit
tabl
right
side
subgroup
patient
progress
radiograph
proven
lrd
lymphocyt
count
less
time
rsv
uri
onset
remain
signific
risk
factor
progress
lrd
probabl
progress
lrd
rsv
uri
lymphocyt
count
uri
onset
shown
figur
determin
whether
highdos
ribavirin
treatment
effect
vari
base
baselin
lymphocyt
count
perform
stratifi
analysi
supplementari
figur
appear
stronger
trend
toward
treatment
effect
low
lymphocyt
strata
total
lymphocyt
count
neither
result
reach
statist
signific
also
fit
multivari
model
examin
effect
corticosteroid
dose
time
uri
diagnosi
adjust
lymphocyt
count
smoke
statu
highdos
ribavirin
tbi
steroid
dose
associ
progress
lrd
data
shown
store
rsv
cultur
isol
subtyp
quantit
realtim
rtpcr
patient
could
identifi
rsv
infect
episod
rsv
subtyp
patient
subtyp
patient
subtyp
b
tabl
rsv
subtyp
significantli
associ
progress
univari
analysi
tabl
rsv
subtypespecif
neutral
antibodi
rsv
vs
rsv
b
level
examin
donor
recipi
pretranspl
posttranspl
close
time
rsv
uri
none
show
statist
signific
associ
progress
tabl
similarli
weekli
ivig
infus
impact
risk
progress
tabl
effect
immun
reconstitut
progress
examin
progressor
nonprogressor
compar
chang
alc
time
progressor
alc
uri
onset
lrd
onset
compar
median
time
progress
uri
lrd
day
alc
time
uri
onset
day
later
compar
nonprogressor
progressor
median
alc
uri
lrd
onset
respect
supplementari
figur
nonprogressor
median
alc
uri
onset
uri
day
supplementari
figur
median
rang
chang
alc
progressor
vs
nonprogressor
respect
figur
alc
chang
rate
per
day
also
examin
calcul
slope
alc
chang
alc
lrd
uri
onset
divid
day
uri
lrd
progressor
alc
uri
uri
onset
divid
nonprogressor
median
rang
slope
progressor
vs
nonprogressor
vs
figur
signific
differ
group
chang
alc
p
slope
alc
p
rsv
infect
patient
undergo
hct
result
respiratori
failur
death
lrd
develop
rsv
diseas
progress
univers
observ
rate
progress
rang
mean
identif
risk
factor
associ
progress
assess
potenti
treatment
modal
import
care
patient
studi
design
determin
signific
viral
subtyp
typespecif
neutral
antibodi
previous
untest
factor
could
associ
progress
lower
respiratori
tract
diseas
found
smoke
condit
highdos
tbi
absolut
lymphocyt
count
alc
time
uri
onset
significantli
associ
progress
tabl
wherea
viral
subtyp
rsvspecif
neutral
antibodi
lung
function
lymphocyt
engraft
dynam
appear
similar
progressor
nonprogressor
tabl
figur
date
lymphopenia
establish
risk
factor
progress
rsv
uri
lrd
hct
recipi
valid
associ
statist
model
adjust
import
risk
factor
defin
first
time
knowledg
protect
level
alc
studi
determin
lymphocyt
count
time
uri
onset
associ
complet
protect
diseas
progress
although
absolut
level
lymphocyt
appear
extrem
predict
subsequ
lrd
lymphocyt
engraft
dynam
appar
effect
potenti
role
lymphocyt
immun
reconstitut
suspect
risk
factor
rsv
lrd
develop
sever
rsv
diseas
known
occur
frequent
infect
occur
engraft
immun
reconstitut
inflammatori
syndrom
iri
wellknown
phenomenon
observ
clinic
deterior
set
infect
face
immun
restor
antiretrovir
therapi
certain
individu
infect
human
immunodefici
viru
hiv
iri
also
report
nonhiv
set
hct
solid
organ
transplant
recipi
autoimmun
diseas
cancer
therapi
multipl
pathogen
exist
immun
reconstitut
phenomenon
context
rsv
diseas
progress
hct
recipi
systemat
analyz
lymphocyt
count
found
critic
risk
factor
progress
examin
effect
lymphocyt
count
chang
progress
uri
lrd
test
whether
progress
lrd
associ
increas
lymphocyt
count
thu
form
iri
possibl
iri
due
respiratori
viru
infect
patient
parainfluenza
patient
rsv
report
sever
combin
immunodefici
diseas
scid
patient
present
postengraft
pneumon
hct
howev
observ
differ
lymphocyt
engraft
dynam
progressor
nonprogressor
figur
suggest
profound
lymphopenia
associ
immun
defect
rather
iri
phenomenon
respons
progress
lrd
rsvspecif
antibodi
play
import
role
prevent
rsv
diseas
young
children
palivizumab
prophylaxi
document
prevent
seriou
rsv
diseas
young
children
underli
cardiac
pulmonari
diseas
shown
limit
success
treatment
situat
elderli
immunocompet
person
rsv
antibodi
level
associ
hospit
icu
care
recent
retrospect
pool
review
manag
rsv
infect
adult
recipi
hct
show
treatment
intervent
aerosol
ribavirin
alon
ribavirin
combin
immunoglobulin
rsv
specif
immunoglobulin
palivizumab
reduc
progress
almost
onethird
compar
treatment
anoth
small
retrospect
analysi
palivizumab
given
rsv
uri
show
benefici
effect
overal
import
serum
rsvab
level
protect
hct
patient
rsv
diseas
progress
known
present
good
evid
support
use
patient
rsv
uri
base
data
hypothes
differ
rsv
antibodi
level
would
influenc
progress
outcom
rsv
infect
effect
preexist
rsv
antibodi
level
donor
recipi
hct
posttranspl
period
near
time
rsv
infect
occur
examin
analys
show
role
preexist
antibodi
level
progress
rsv
diseas
upper
lower
tract
infect
tabl
although
observ
differ
antibodi
level
progressor
nonprogressor
studi
first
knowledg
measur
rsv
b
subtyp
specif
antibodi
level
hct
recipi
donor
optim
rsvspecif
antibodi
level
hct
recipi
donor
prevent
progress
hct
recipi
known
data
provid
refer
futur
studi
differ
rsv
diseas
sever
base
subtyp
b
suggest
children
primari
infect
literatur
rsv
b
typic
cocircul
commun
type
also
detect
immunocompromis
popul
correl
rsv
subtyp
diseas
progress
subject
demonstr
rsv
subtyp
significantli
associ
progress
diseas
tabl
although
abl
perform
analysi
rel
small
subset
patient
unabl
detect
trend
therefor
effect
subtyp
diseas
progress
present
like
small
activ
smoke
hct
risk
factor
progress
studi
novel
observ
immunocompromis
patient
popul
potenti
modifi
factor
household
smoke
long
identifi
risk
rsv
bronchiol
pediatr
popul
studi
systemat
immunocompromis
adult
popul
also
examin
role
steroid
treatment
vari
dose
presenc
vari
degre
gvhd
time
transplant
rsv
infect
transplant
host
factor
found
statist
signific
associ
lack
associ
steroid
dose
import
clinic
practic
physician
often
wonder
whether
small
dose
steroid
given
eas
obstruct
pattern
rapid
taper
initi
patient
alreadi
receiv
steroid
mostli
gvhd
although
random
trial
data
would
suggest
moder
dose
system
corticosteroid
may
associ
progress
lrd
studi
find
statist
signific
effect
highdos
ribavirin
given
rsv
uri
howev
number
patient
treat
rel
small
trend
consist
report
literatur
preemptiv
aerosol
ribavirin
evalu
adequ
power
random
control
trial
immunocompromis
patient
although
recent
analys
suggest
benefici
effect
addit
case
seri
studi
report
effect
oral
intraven
ribavirin
treatment
need
evalu
studi
sever
strength
limit
although
includ
clinic
data
larg
number
patient
initi
present
rsv
uri
sera
rsv
specif
antibodi
test
avail
subset
recipi
donor
less
half
rsv
viru
subtyp
also
avail
patient
therefor
smaller
effect
size
associ
rsv
subtyp
rsvspecif
antibodi
level
may
miss
despit
limit
first
studi
knowledg
examin
rsv
subtyp
specif
antibodi
level
hct
recipi
concurr
viru
subtyp
addit
studi
examin
effect
immun
reconstitut
although
analyz
overal
lymphocyt
engraft
dynam
unabl
evalu
effect
specif
tcell
subset
data
avail
cell
avail
studi
conclus
among
hct
recipi
present
rsv
uri
identifi
smoke
condit
highdos
tbi
cgi
alc
time
uri
onset
signific
risk
factor
associ
progress
also
observ
alc
complet
protect
rsv
diseas
progress
import
lymphocyt
count
lack
c
import
antibodi
level
suggest
character
rsvspecif
cellmedi
immun
warrant
